Seelos Therapeutics Stock EBITDA
Seelos Therapeutics fundamentals help investors to digest information that contributes to Seelos Therapeutics' financial success or failures. It also enables traders to predict the movement of Seelos OTC Stock. The fundamental analysis module provides a way to measure Seelos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seelos Therapeutics otc stock.
Seelos |
Seelos Therapeutics OTC Stock EBITDA Analysis
Seelos Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Seelos Therapeutics EBITDA | (40.44 M) |
Most of Seelos Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seelos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Seelos Therapeutics reported earnings before interest,tax, depreciation and amortization of (40.44 Million). This is 104.61% lower than that of the Pharmaceuticals sector and 140.38% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.04% higher than that of the company.
Seelos EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seelos Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Seelos Therapeutics could also be used in its relative valuation, which is a method of valuing Seelos Therapeutics by comparing valuation metrics of similar companies.Seelos Therapeutics is currently under evaluation in ebitda category among its peers.
Seelos Fundamentals
Return On Equity | -5.84 | |||
Return On Asset | -2.61 | |||
Profit Margin | 2.03 % | |||
Operating Margin | (8.35) % | |||
Current Valuation | 10.45 M | |||
Shares Outstanding | 581 K | |||
Shares Owned By Insiders | 0.49 % | |||
Shares Owned By Institutions | 4.46 % | |||
Number Of Shares Shorted | 170.89 K | |||
Price To Book | 15.10 X | |||
Price To Sales | 0.37 X | |||
Revenue | 2.2 M | |||
Gross Profit | (46.65 M) | |||
EBITDA | (40.44 M) | |||
Net Income | (37.88 M) | |||
Cash And Equivalents | 41.25 M | |||
Cash Per Share | 0.39 X | |||
Total Debt | 14.23 M | |||
Debt To Equity | 0.73 % | |||
Current Ratio | 3.60 X | |||
Book Value Per Share | (135.50) X | |||
Cash Flow From Operations | (23.91 M) | |||
Short Ratio | 0.14 X | |||
Earnings Per Share | 351.04 X | |||
Target Price | 120.0 | |||
Beta | 1.85 | |||
Market Capitalization | 743.68 K | |||
Total Asset | 5.42 M | |||
Retained Earnings | (252.63 M) | |||
Working Capital | (33.52 M) | |||
Net Asset | 5.42 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |